Gastric Cancer Testing, Treatment and Prevention: Technologies and Global Markets

October 2015 •
183 pages •
Report ID: 3348546 •
Format: PDF

Summary
Table of contents

This BCC Research report reviews global markets for biologic therapeutics for gastric cancer and forecasts trends for use of diagnostics, screening and cancer treatment through 2020.

Highlights

-The global gastric cancer diagnostic/screening and treatment market totaled $235.5 billion in 2014. This market is expected to grow from $241.7 billion in 2015 to nearly $318.3 billion by 2020, with a compound annual growth rate (CAGR) of 5.7%.
-The diagnosis/screening segment of the gastric cancer market should total $240.0 billion in 2015 and $315.0 billion by 2020, registering a CAGR of 5.6%.
-The drug therapy segment of this market is expected to increase from $1.5 billion in 2015 to nearly $3.3 billion by 2020, with a CAGR of 14.0%.

INTRODUCTION

STUDY GOALS AND OBJECTIVES

This report, HLC174A – Gastric Cancer Testing, Treatment and Prevention: Technologies and Global Markets, provides a detailed overview and thorough analysis of the present and future global market for gastric cancer diagnostics and therapeutics.

This report analyzes in detail the gastric cancer markets. The report includes products in this market and detailed analyses of markets and competitive environments as well as gastric cancer markets in newly emerging therapeutics and their impact on the market. The report includes information about significant products, key players, issues and trends, current market status of cancer biotherapeutics, strengths, weaknesses, opportunities and threats facing various gastric cancer therapeutics already on the market, major issues involved in the research and development of more effective cancer therapeutics and new cancer therapeutics in development and in clinical trials.

REASONS FOR DOING THE STUDY

The rise in the number of cancer diagnoses and wider access and greater affordability of treatment regimes in developing countries will stimulate growth in the world of gastric cancer therapies market. Stomach cancer is the fifth most common cancer in the world, with 952,000 new cases diagnosed in 2012. The bacterium Helicobacter
pylori is an important cause of distal stomach cancers. Also, Epstein-Barr virus is carcinogenic to humans and has been linked to stomach cancers in some studies.

Consumption of salt and salty foods probably increases the risk of colorectal cancer and consumption of non-starchy vegetables, allium vegetables and fruits probably protect against this cancer.

Newer therapeutics have emerged in the past few years that have had a significant impact on cancer treatment and health. The market for gastric cancer therapies is expected to be about $3.2 billion in 2020. The demand for newer and innovative oncology drugs will continue to grow as healthcare systems worldwide emphasize cancer detection and treatment. This study covers current market status of cancer biotherapeutics, strengths, weaknesses, various cancer biotherapeutics already on the market, major issues involved in the research and development of more effective cancer therapeutics and new cancer therapeutics in development and in clinical trials

SCOPE AND FORMAT

This report will give an overall update on gastric cancer. It will review global markets for biologic therapeutics for gastric cancer and will forecast trends for use of diagnostics, screening and cancer treatment through 2020. It will cover important therapies, biologics, diagnostics, market share, products on the market and market share by company and statistical information for types of cancers prevalent worldwide, with special emphasis on the U.S. market.

Current issues and trends affecting the industry, costs and factors influencing demand will be discussed. The report covers diagnostics, therapeutics, biological products in development, biological products in clinical trials, and currently marketed and late-stage developments in biologic cancer products. In addition, this report includes:

Treatment trends and sales patterns across major cancer indications with market performance of major pharmaceutical companies.

Forecast sales of leading products across major indications to 2020.

Ahmad helps you find the right report:

+1 718 618 4302
Contact by email

FAQ

Testimonials

The market research advisor answered my questions quickly and professionally. ReportBuyer's team did their best to ensure that I felt comfortable before making the investment to purchase the report.

Cristian Nunez

Director of Corporate Development Chugach Alaska Corporation

My overall experience with ReportBuyer today has been very positive, and I must thank you for your patience (...). Also, the sample you sent me and the explanations provided were very helpful.

D. Lescuyer

Executive Vice President Oral Business at Skyepharma

The research specialist was very helpful, and proposed the best content for my needs. ReportBuyer also offered a great follow-up, thanks for everything !

P. Thompson

EMEA Managing Director

We were satisfied with the support that ReportBuyer's team provided. Thanks to their recommendations, the report we purchased provided exactly what we want.

Y. Wang

Business Analyst

We didn't have time to do the research internally, and thanks to ReportBuyer's team we were able to find the appropriate data.

S. Chen

Research Coordinator

I was impressed by the customer service: it was fast, responsive, and 100% professional !

D. Krivan

Market Research Analyst

The research specialist provided prompt and helpful service. He also followed up to ensure I had all the information to deliver my business development plan.

C. Adams

Senior Business Development Manager